PL3121280T3 - Antysensowne kompozycje i sposoby ich wytwarzania i stosowania - Google Patents

Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Info

Publication number
PL3121280T3
PL3121280T3 PL16187284.1T PL16187284T PL3121280T3 PL 3121280 T3 PL3121280 T3 PL 3121280T3 PL 16187284 T PL16187284 T PL 16187284T PL 3121280 T3 PL3121280 T3 PL 3121280T3
Authority
PL
Poland
Prior art keywords
preparation
methods
antisense compositions
antisense
compositions
Prior art date
Application number
PL16187284.1T
Other languages
English (en)
Inventor
Sergio Baroni
Salvatore Bellinvia
Francesca Viti
Original Assignee
Nogra Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Limited filed Critical Nogra Pharma Limited
Publication of PL3121280T3 publication Critical patent/PL3121280T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL16187284.1T 2008-11-13 2009-11-13 Antysensowne kompozycje i sposoby ich wytwarzania i stosowania PL3121280T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425727 2008-11-13
US15229709P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
PL3121280T3 true PL3121280T3 (pl) 2025-09-01

Family

ID=42101499

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09756431T PL2364360T3 (pl) 2008-11-13 2009-11-13 Antysensowne kompozycje i sposoby ich wytwarzania i stosowania
PL16187284.1T PL3121280T3 (pl) 2008-11-13 2009-11-13 Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09756431T PL2364360T3 (pl) 2008-11-13 2009-11-13 Antysensowne kompozycje i sposoby ich wytwarzania i stosowania

Country Status (23)

Country Link
US (7) US8912154B2 (pl)
EP (2) EP2364360B1 (pl)
JP (7) JP5719776B2 (pl)
KR (2) KR101921014B1 (pl)
CN (2) CN107007616A (pl)
AU (4) AU2009315898B2 (pl)
CA (2) CA2743329C (pl)
CY (1) CY1119140T1 (pl)
DK (2) DK2364360T3 (pl)
ES (2) ES2627745T3 (pl)
FI (1) FI3121280T3 (pl)
HR (2) HRP20170926T1 (pl)
HU (2) HUE071668T2 (pl)
LT (2) LT2364360T (pl)
MX (3) MX346335B (pl)
NZ (1) NZ592673A (pl)
PL (2) PL2364360T3 (pl)
PT (2) PT3121280T (pl)
RS (2) RS66973B1 (pl)
RU (2) RU2739302C2 (pl)
SI (2) SI3121280T1 (pl)
SM (2) SMT201700346T1 (pl)
WO (1) WO2010054826A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PT3121280T (pt) 2008-11-13 2025-07-01 Nogra Pharma Ltd Composições antissentido e método de fabrico e utilização das mesmas
MX350087B (es) 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
ITCO20120008A1 (it) * 2012-03-01 2013-09-02 Nuovo Pignone Srl Metodo e sistema per monitorare la condizione di un gruppo di impianti
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US20140122184A1 (en) * 2012-10-29 2014-05-01 Elwha Llc Food Supply Chain Automation Grocery Information System And Method
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof
MX363746B (es) * 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
WO2015011694A2 (en) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
JP6583954B2 (ja) * 2015-01-08 2019-10-02 日東電工株式会社 展示装置および映像展示方法
WO2016130832A1 (en) * 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
JP2018531936A (ja) * 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
MA44309A (fr) 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2017144725A1 (en) 2016-02-26 2017-08-31 Nogra Pharma Limited Methods of treating lactose intolerance
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. MODULATORS OF SMAD7 EXPRESSION
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
US20220145303A1 (en) 2019-02-26 2022-05-12 Nogra Pharma Limited Fragile x mental retardation protein interfering oligonucleotides and methods of using same
MX2022005900A (es) 2019-11-15 2022-06-24 Nogra Pharma Ltd Agentes antisentido de il-34 y metodos de uso de los mismos.
AU2021260967A1 (en) * 2020-04-24 2022-10-20 Nogra Pharma Limited Compositions of SMAD7 antisense oligonucleotides (ASO) and methods of using the same
EP4341403A1 (en) 2021-05-17 2024-03-27 Nogra Pharma Limited Il-34 antisense agents and methods of using same
WO2022243299A1 (en) 2021-05-17 2022-11-24 Nogra Pharma Limited Il-34 antisense agents and methods of using same
CN119452086A (zh) 2021-12-03 2025-02-14 奎里斯公司 具有修饰的主链化学的gapmer反义寡核苷酸
KR20250164821A (ko) 2023-03-28 2025-11-25 노그라 파마 리미티드 회장낭염의 치료를 위한 smad7 억제성 안티센스 올리고뉴클레오티드 (aso) 및 그의 사용 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5795858A (en) 1993-09-24 1998-08-18 Peptide Technology Limited Treatment or prevention of Crohn's disease and/or ulcerative colitis
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
KR20010020370A (ko) 1997-04-30 2001-03-15 파샬 비. 린네 향상된 생체이용률을 갖는 올리고뉴클레오티드
IE970794A1 (en) 1997-09-24 2000-08-23 Elan Corp Plc Composition and method for enhancing paracellular transport across cell layers
DE69824748T2 (de) * 1997-09-26 2005-08-25 Celltech Pharma Europe Ltd. Pharmazeutische zusammensetzung für die behandlung von enzündlichen darmerkrankungen
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1080103A4 (en) 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ZA200502318B (en) * 2002-10-16 2006-11-29 Takeda Pharmaceutical Controlled release preparation
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
TW200514579A (en) * 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
RU2375047C2 (ru) * 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
JP2008521756A (ja) 2004-11-26 2008-06-26 メディキュア インターナショナル インコーポレイテッド ピリドキサール−５’−ホスフェートの新規配合物及び調製方法
CN101151035A (zh) * 2004-12-02 2008-03-26 Isis制药公司 用于治疗炎性肠病的治疗性反义寡核苷酸组合物
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
JP2009502957A (ja) 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
WO2007047553A2 (en) 2005-10-14 2007-04-26 Zweig Jack I Methods and compositions for treatment of prostate intraepithelial neoplasia
CN1850135A (zh) * 2006-03-09 2006-10-25 陈世忠 一种鸦胆子油肠溶软胶囊制剂及其制备方法和其应用
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CN103120653B (zh) * 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
PT3121280T (pt) 2008-11-13 2025-07-01 Nogra Pharma Ltd Composições antissentido e método de fabrico e utilização das mesmas
US9364495B2 (en) * 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
MX350087B (es) 2011-09-15 2017-08-24 Nogra Pharma Ltd Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7.
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
MX363746B (es) 2013-03-15 2019-04-01 Nogra Pharma Ltd Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
JP2017529321A (ja) 2014-07-28 2017-10-05 ノグラ ファーマ リミテッド 炎症性腸疾患を診断ならびに処置するための方法および組成物
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
EP3420085A1 (en) 2016-02-24 2019-01-02 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
HRP20170926T1 (hr) 2017-09-22
DK3121280T3 (da) 2025-06-30
KR20170092719A (ko) 2017-08-11
MX346335B (es) 2017-03-14
KR101921014B1 (ko) 2018-11-21
CN107007616A (zh) 2017-08-04
US9499819B2 (en) 2016-11-22
EP2364360A1 (en) 2011-09-14
HUE032368T2 (en) 2017-09-28
JP6530772B2 (ja) 2019-06-12
LT2364360T (lt) 2017-08-10
US9314434B2 (en) 2016-04-19
RU2739302C2 (ru) 2020-12-22
JP7377624B2 (ja) 2023-11-10
US20170107520A1 (en) 2017-04-20
MX2011005042A (es) 2011-08-17
SI3121280T1 (sl) 2025-08-29
PT3121280T (pt) 2025-07-01
KR20110086599A (ko) 2011-07-28
JP2012508705A (ja) 2012-04-12
CN102216458A (zh) 2011-10-12
RS66973B1 (sr) 2025-07-31
AU2015246097B2 (en) 2018-01-18
EP3121280B1 (en) 2025-04-09
US20150232854A1 (en) 2015-08-20
US20150125523A1 (en) 2015-05-07
CA3085272A1 (en) 2010-05-20
AU2009315898B2 (en) 2015-07-23
ES3034412T3 (en) 2025-08-18
AU2020202813A1 (en) 2020-05-21
RU2016127232A (ru) 2018-12-06
US9982264B2 (en) 2018-05-29
PL2364360T3 (pl) 2017-09-29
PT2364360T (pt) 2017-06-27
AU2015246097A1 (en) 2015-11-12
RU2016127232A3 (pl) 2019-12-18
JP2015232039A (ja) 2015-12-24
AU2017279624B2 (en) 2020-02-06
WO2010054826A1 (en) 2010-05-20
SMT201700346T1 (it) 2017-09-07
US20120015033A1 (en) 2012-01-19
RU2011123876A (ru) 2012-12-20
US20190374472A1 (en) 2019-12-12
US20160222383A1 (en) 2016-08-04
RU2593939C2 (ru) 2016-08-10
AU2017279624A1 (en) 2018-01-18
RS56049B1 (sr) 2017-09-29
JP6095744B2 (ja) 2017-03-15
NZ592673A (en) 2013-01-25
FI3121280T3 (fi) 2025-07-02
LT3121280T (lt) 2025-07-25
JP2014196356A (ja) 2014-10-16
HUE071668T2 (hu) 2025-09-28
CN102216458B (zh) 2017-05-24
EP3121280A1 (en) 2017-01-25
CY1119140T1 (el) 2018-02-14
AU2009315898A1 (en) 2010-05-20
JP2021138778A (ja) 2021-09-16
US10272047B2 (en) 2019-04-30
US20210290656A1 (en) 2021-09-23
US8912154B2 (en) 2014-12-16
JP2019151658A (ja) 2019-09-12
ES2627745T3 (es) 2017-07-31
JP2023138750A (ja) 2023-10-02
SI2364360T1 (sl) 2017-08-31
CA2743329C (en) 2020-09-01
KR101767145B1 (ko) 2017-08-11
MX2023008408A (es) 2023-10-19
EP2364360B1 (en) 2017-03-22
CA2743329A1 (en) 2010-05-20
JP5719776B2 (ja) 2015-05-20
SMT202500239T1 (it) 2025-09-12
HRP20250744T1 (hr) 2025-08-15
DK2364360T3 (en) 2017-06-19
JP2017075184A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
PL3121280T3 (pl) Antysensowne kompozycje i sposoby ich wytwarzania i stosowania
PL3812360T3 (pl) Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania
IL252119B (en) Improved cell composition and methods of making the same
PT2424372T (pt) Composições antimicrobianas e métodos de uso relacionados
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI1008280A2 (pt) Formulações prebióticas e métodos mde uso
PL2624702T3 (pl) Kompozycje przeciwko tworzeniu biofilmów oraz sposoby ich zastosowania
SMT201500212B (it) Composizioni di antagonisti di pd-1 e metodi di utilizzo
BRPI0906980A2 (pt) Composição de derivados e maleatados
ZA201008232B (en) Lipid-containing compositions and methods of use thereof
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
PL2346327T3 (pl) Kompozycje biobójcze i sposoby stosowania
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
BRPI0917707A2 (pt) composições biocidas potencializadas e métodos de uso
IL201364A0 (en) Gas-effusing compositions and methods of making and using same
IL247929B (en) Stable compositions of 595–sns and methods for their preparation
GB0812890D0 (en) Compositions and methods of making compositions
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
BRPI1010278A2 (pt) composições para preparação do intestino e métodos de uso destas
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
PL2366013T3 (pl) Kompozycje do prania i sposoby ich zastosowania
BRPI0922033A2 (pt) composições e métodos de uso de variantes de trombomodulina
PL2651392T3 (pl) Kompozycje stałe zawierające flurbiprofen, sposoby ich wytwarzania oraz ich zastosowanie